ArticleNeurology2026
Rasch-Built Overall Disability Scale for Chronic Idiopathic Axonal Polyneuropathy.
Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesChronic idiopathic axonal polyneuropathy (CIAP) is a common type of chronic polyneuropathy that often affects health-related quality of life. Currently, no patient-reported disease-specific outcome measure is available to assess functional deficit in patients with CIAP. The aim of this study was to construct a patient-reported Rasch-built interval scale for patients with CIAP.
methodsA historic prospective cohort study was conducted to develop a CIAP-specific Rasch-built overall disability scale (CIAP-RODS). The preliminary scale (pre-CIAP-RODS) comprised 196 items, including 146 activity and participation items selected from the World Health Organization International Classification of Functioning, Disability and Health and 50 expert-derived items formulated in collaboration with a CIAP patients advocacy group. Participants were patients with CIAP who were requested to score their perceived difficulty to perform each item as (0) unable to perform; (1) able to perform, but with difficulty; or (2) easily performed, without difficulty. For test-retest reliability studies, 150 participants completed the pre-CIAP-RODS twice with an interval of 2-4 weeks. The pre-CIAP-RODS was subjected to Rasch analyses (RUMM2030+) to develop the final CIAP-RODS, and external validity was assessed by examining associations with the European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L).
resultsOf 551 eligible patients invited, 268 completed the pre-CIAP-RODS (mean age 72 years; 31% female; median disease duration 14 years). Patients with relevant comorbidities or newly identified risk factors of polyneuropathy were excluded. The pre-CIAP-RODS was subjected to Rasch analyses and did not meet the Rasch model expectations. In a systematic and stepwise manner, items were removed based on disordered thresholds, misfit statistics, local dependency, previously reported patient perceptions, and clinical applicability, resulting in a final 24-item CIAP-RODS that fulfilled Rasch model requirements. Test-retest reliability was good, internal validity was robust (person separation index 0.95), and significant associations between CIAP-RODS person location and EQ-5D-3L item scores indicated good discriminative external validity. DISCUSSION: The 24-item CIAP-RODS is a disease-specific interval measure developed for detection of activity and participation limitations in patients with CIAP. Use of the CIAP-RODS in future studies is recommended to evaluate longitudinal changes in the disease course. Further studies are needed to determine responsiveness and cross-cultural validity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.